Pharmaceuticals Banned from Giving Medics Incentives
Pharmaceutical companies have been banned from giving financial or related incentives to healthcare professionals in an attempt to influence their prescription of drugs to patients.
In its new code of practice, the Kenya Association of Pharmaceutical Industry has proscribed the offering of any financial or material benefit, including grants, scholarships, subsidies, support, consulting contracts or educational or practice-related items, to doctors as an inducement for prescribing, recommending, purchasing, supplying or administering particular products.
Those who will break the rule risk a fine that will be determined by the association’s ethics committee.
“All our members are now bound by the code of practice, which restricts them from corrupting doctors or any other healthcare professionals,” said Kapi chairperson Anastasia Nyalita, adding that the new code aims at enhancing public trust.
Penalties will be assessed by the Ethics and Compliance Committee, in line with the Arbitration Act. According to Dr Nyalita, strict enforcement of the code has been triggered by the need for more transparency and accountability in interactions between healthcare professionals and the public.
The rules are also meant to curb unethical practices. The code is a collection of principles derived from The International Federation of Pharmaceutical Manufacturers and Associations Code of Practice, 2012, European Federation of Pharmaceutical Industries and Association, and South Africa Code of Marketing Practice.
But the code allows medical workers to receive “patient health related” gifts. These items include anatomical models, stethoscopes, medical textbooks, journals and magazines.
Looking for chemical products? Let suppliers reach out to you!
2026-07-08
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Vivo Capital Co-founded! Xinrui Won Exclusive Rights to 4 RNAi Drugs in Greater China
-
What Are The Industrial Uses Of Glycerin
-
Chinese herbal medicine traceability system construction blueprint more clearly
-
These policies will affect all pharmaceutical companies!
-
Brazil sets up a special team to increase its own raw materials
-
Update of negative list of foreign investment access
-
Analysis of Hot Varieties in Antiviral Raw Material Market
-
API China:Stimulate industry innovation vitality
-
Raffles Pharma and Xuancheng Menova Pharmaceuticals reached a cooperation
-
2019 CPhI Worldwide Recap
Recommend Reading
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
Iran Closes Strait of Hormuz to All Vessels: Global Chemical Trade Gets Choked
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
Safic-Alcan Acquires Anders, Expanding Latin American Presence
-
BASF Expands Architectural Coatings Dispersion Production Capacity in Turkey